Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells

NMR in Biomedicine

Volumn 25, Issue 5, 2012, Pages 746-754

  Shah, Tariq ^a   Stasinopoulos, Ioannis ^a   Wildes, Flonne ^a   Kakkad, Samata ^a   Artemov, Dmitri ^a   Bhujwalla, Zaver M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Choline kinase; COX 2; Invasion; Lipid droplets; MRS

Indexed keywords

BREAST CANCER; CHOLINE KINASE; COX-2; INVASION; LIPID DROPLETS; MRS;

BLOOD VESSELS; CYTOLOGY; DISEASES; ENZYME ACTIVITY; GENE EXPRESSION; MEDICAL IMAGING; METABOLISM; OXYGENATION; PATHOLOGY; PHOSPHOLIPIDS; PHYSIOLOGY; RNA;

CELLS;

BIOLOGICAL MARKER; CHOLINE; CHOLINE KINASE; CYCLOOXYGENASE 2; FAT DROPLET; MATRIX METALLOPROTEINASE; PHOSPHORYLCHOLINE; SHORT HAIRPIN RNA; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BREAST CANCER; CANCER CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DOWN REGULATION; EXTRACELLULAR MATRIX; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIPID METABOLISM; METASTASIS; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGENATION; PERFUSION; PERISTALTIC PUMP; PH; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN TARGETING; TEMPERATURE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHOLINE; CHOLINE KINASE; CYCLOOXYGENASE 2; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM INVASIVENESS; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE;

EID: 84859646614     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1789     Document Type: Article

References (49)

1. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000; 69: 145-182.
2. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol. 2004; 68: 1089-1100.
3. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62: 632-635.
4. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 2001; 108: 25-30.
5. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007; 9: 210.
6. Singh-Ranger G, Salhab M, Mokbel K. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res. Treat. 2008; 109: 189-198.
7. Wang D, Dubois RN. Eicosanoids and cancer. Nat. Rev. Cancer 2010; 10: 181-193.
8. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58: 362-366.
9. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002; 62: 4903-4908.
10. Dormond O, Bezzi M, Mariotti A, Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J. Biol. Chem. 2002; 277: 45838-45846.
11. Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem. Biophys. Res. Commun. 2002; 299: 886-890.
12. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem. 2000; 7: 1163-1170.
13. Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, Levine AC. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin. Exp. Metastasis 1999; 17: 687-694.
14. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 2001; 276: 18563-18569.
15. Stasinopoulos I, Mori N, Bhujwalla ZM. The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. Neoplasia 2008; 10: 1163-1169.
16. Stasinopoulos I, O'Brien DR, Wildes F, Glunde K, Bhujwalla ZM. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol. Cancer Res. 2007; 5: 435-442.
17. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005; 65: 11034-11043.
18. Pilatus U, Ackerstaff E, Artemov D, Mori N, Gillies RJ, Bhujwalla ZM. Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber. Neoplasia 2000; 2: 273-279.
19. Ackerstaff E, Gimi B, Artemov D, Bhujwalla ZM. Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia 2007; 9: 222-235.
20. Pilatus U, Shim H, Artemov D, Davis D, van Zijl PC, Glickson JD. Intracellular volume and apparent diffusion constants of perfused cancer cell cultures, as measured by NMR. Magn. Reson. Med. 1997; 37: 825-832.
21. 1H homonuclear editing of rat brain using semiselective pulses. Proc. Natl. Acad. Sci. USA 1985; 82: 3115-3118.
22. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 2003; 5: 533-545.
23. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011; 4: 271-290.
24. Carey MA, Germolec DR, Langenbach R, Zeldin DC. Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot. Essent. Fatty Acids 2003; 69: 157-162.
25. Lee KH, Kim HS, El-Sohemy A, Cornelis MC, Uhm WS, Bae SC. Cyclooxygenase-2 genotype and rheumatoid arthritis. J. Rheumatol. 2006; 33: 1231-1234.
26. Liclican EL, Nguyen V, Sullivan AB, Gronert K. Selective activation of the prostaglandin E2 circuit is a key component of chronic injury-induced pathological angiogenesis. Invest. Ophthalmol. Vis. Sci. 2010; 51: 6311-6320.
27. Huang Y, Song N, Ding Y, Yuan S, Li X, Cai H, Shi H, Luo Y. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res. 2009; 69: 7529-7537.
28. Nyberg P, Ylipalosaari M, Sorsa T, Salo T. Trypsins and their role in carcinoma growth. Exp. Cell Res. 2006; 312: 1219-1228.
29. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Moscow) 2002; 67: 92-98.
30. Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, Zanker KS, Metzger R, Schneider PM, Gerke V, Thomas M, Berdel WE, Serve H, Muller-Tidow C. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004; 64: 5564-5569.
31. Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res. Treat. 2010; 124: 27-38.
32. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002; 62: 7203-7206.
33. Prosperi JR, Mallery SR, Kigerl KA, Erfurt AA, Robertson FM. Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2. Prostaglandins Other Lipid Mediat. 2004; 73: 249-264.
34. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, Yang PC. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int. J. Cancer 2005; 115: 545-555.
35. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer 2007; 120: 1721-1730.
36. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl. Cancer Inst. 2002; 94: 1197-1203.
37. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5: 303-324.
38. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005; 65: 9369-9376.
39. Shah T, Wildes F, Penet MF, Winnard PT, Jr., Glunde K, Artemov D, Ackerstaff E, Gimi B, Kakkad S, Raman V, Bhujwalla ZM. Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed. 2010; 23: 633-642.
40. Stasinopoulos I, O'Brien DR, Bhujwalla ZM. Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2. Cancer Biol. Ther. 2009; 8: 31-35.
41. Glunde K, Shah T, Winnard PT Jr, Raman V, Takagi T, Vesuna F, Artemov D, Bhujwalla ZM. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res. 2008; 68: 172-180.
42. Chan BS, Endo S, Kanai N, Schuster VL. Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT. Am. J. Physiol. Renal Physiol. 2002; 282: F1097-F1102.
43. Delikatny EJ, Cooper WA, Brammah S, Sathasivam N, Rideout DC. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res. 2002; 62: 1394-1400.
44. Delikatny EJ, van Holst Pellekaan CJ, King NJ. Autologous lymphocyte-monocyte co-culture increases NMR-visible and cytoplasmic lipids in the absence of increased markers of lymphocyte activation. Biochim. Biophys. Acta 2001; 1533: 243-254.
45. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, Samid D, Poptani H, Glickson JD, Delikatny EJ. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim. Biophys. Acta 2005; 1734: 1-12.
46. Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem. 2006; 6: 221-232.
47. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin. Oncol. 2004; 31: 12-21.
48. Krysan K, Reckamp KL, Sharma S, Dubinett SM. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem. 2006; 6: 209-220.
49. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005; 128: 1445-1461.